1250939-12-8

Basic information

• Product Name: (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester
• Synonyms: (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester
• CAS NO: 1250939-12-8
• Molecular Weight: 426.307
• Mol File: 1250939-12-8.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester(1250939-12-8)
• EPA Substance Registry System: (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester(1250939-12-8)

Safety Data

• Hazardous Substances Data: 1250939-12-8(Hazardous Substances Data)

Upstream product

• 676560-84-2 (2S,5S)-5-methylpyrrolidine-2-carboxylic acid ethyl ester 
• 915157-02-7 (2S,5S)-methyl 5-methylpyrrolidine-2-carboxylate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 334769-80-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 99-73-0 para-bromophenacyl bromide 
• 676560-83-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 896733-29-2 (S)-5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 

Downstream Products

• 1250939-15-1 (2S,5S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-5-methylpyrrolidine-1-carboxylate 
• 1250939-15-1 (2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1433280-49-9 4-(4-bromo-phenyl)-2-((2S,5S)-5-methyl-pyrrolidin-2-yl)-1H-imidazole 
• 1378390-49-8 ((S)-1-{(2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1433280-50-2 [(S)-2-methyl-1-((2S,5S)-2-methyl-5-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]carbamic acid methyl ester 
• 1378390-49-8 C₂₁H₂₇BrN₄O₃ 
• 1433280-50-2 methyl ((S)-3-methyl-1-((2S,5S)-2-methyl-5-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate 
• 1359869-71-8 C₂₅H₃₆BN₃O₄ 
• 1393537-53-5 dimethyl ((3-fluoro-4,4'-biphenyldiyl)bis(1H-imidazole-4,2-diyl((2S,5S)-5-methyl-2,1-pyrrolidinediyl)((1S)-1-((2R,6R)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxo-2,1-ethanediyl)))biscarbamate 
• 1393537-73-9 C₃₈H₄₇FN₆O₄ 

Relevant articles and documents

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.